Background It is well known that there was a significant link between preprocedural blood glucose levels and short-term and long-term adverse outcomes in patients undergoing elective PCI. However, the role of preproce...Background It is well known that there was a significant link between preprocedural blood glucose levels and short-term and long-term adverse outcomes in patients undergoing elective PCI. However, the role of preprocedural blood glucose levels as a predictor of adverse events in CKD patients who underwent PCI out of established diabetes has acute were coronary syndrome yet to be （ACS） identified. Methods In our study, we conducted a prospective study of 331 patients with CKD who underwent PCI out of established diabetes. Patients divided into two groups based on pre-procedural glucose levels （hypoglycemia 〈 7.0 mmol/L; hyperglycemia ≥ 7.0 mmol/L）. All patients were followed up prospectively for major adverse cardiovascular events （MACEs） and mortality for 6 months. Results In our cohort, hyperglycemia patients reported a higher incidence of inhospital mortality than hypoglycemia patients （7.5% vs. 0%, P 〈 0.001）. Hyperglycemia patients reported a significantly higher rate of 6-month MACEs （10% vs. 2.4%, P = 0.007）, all cause mortality （7.5% vs. 1.6%, P = 0.015）, and cardiovascular mortality （6.2%vs 1.6%, P = 0.041） compared with hypoglycemia patients with pre-procedural glucose levels 〈 7.0 mmol/L. Multivariate analysis disclosed that a pre-procedural glucose level ≥7.0 mmol/L was a significant independent predictor of MACEs （OR = 2.53, 95% CI 1.68-17.15, P = 0.004）, all cause mortality（OR = 4.6, 95% CI 1.10-18.84, P = 0.036）, and cardiovascular mortality（OR = 6.2, 95% CI 1.53-24.94, P = 0.011） at 6 months in patients after PCI. Conclusion The study suggested that pre-procedural glucose levels are associated with short-term cardiovascular outcome CKD patients who underwent PCI without established diabetes in the setting of ACS.展开更多
文摘Background It is well known that there was a significant link between preprocedural blood glucose levels and short-term and long-term adverse outcomes in patients undergoing elective PCI. However, the role of preprocedural blood glucose levels as a predictor of adverse events in CKD patients who underwent PCI out of established diabetes has acute were coronary syndrome yet to be （ACS） identified. Methods In our study, we conducted a prospective study of 331 patients with CKD who underwent PCI out of established diabetes. Patients divided into two groups based on pre-procedural glucose levels （hypoglycemia 〈 7.0 mmol/L; hyperglycemia ≥ 7.0 mmol/L）. All patients were followed up prospectively for major adverse cardiovascular events （MACEs） and mortality for 6 months. Results In our cohort, hyperglycemia patients reported a higher incidence of inhospital mortality than hypoglycemia patients （7.5% vs. 0%, P 〈 0.001）. Hyperglycemia patients reported a significantly higher rate of 6-month MACEs （10% vs. 2.4%, P = 0.007）, all cause mortality （7.5% vs. 1.6%, P = 0.015）, and cardiovascular mortality （6.2%vs 1.6%, P = 0.041） compared with hypoglycemia patients with pre-procedural glucose levels 〈 7.0 mmol/L. Multivariate analysis disclosed that a pre-procedural glucose level ≥7.0 mmol/L was a significant independent predictor of MACEs （OR = 2.53, 95% CI 1.68-17.15, P = 0.004）, all cause mortality（OR = 4.6, 95% CI 1.10-18.84, P = 0.036）, and cardiovascular mortality（OR = 6.2, 95% CI 1.53-24.94, P = 0.011） at 6 months in patients after PCI. Conclusion The study suggested that pre-procedural glucose levels are associated with short-term cardiovascular outcome CKD patients who underwent PCI without established diabetes in the setting of ACS.
